Home » Posts tagged 'Eric Boyle'
Tag Archives: Eric Boyle
Mendell Helium #MDH – Publication of Circular and Notice of General Meeting
Further to the announcement on 14 October 2024, Mendell Helium announces that a circular and notice of general meeting (“General Meeting”) have been posted to shareholders seeking shareholder approval for the disposal of the Voyager plant-based health and wellness business (the “Disposal”). The General Meeting will be held at 11.30 am on Monday 11 November 2024, at the Company’s offices at Arran House, Arran Road, Perth, Perthshire PH1 3DZ.
The Disposal will constitute a fundamental change of business of the Company under Rule 3.7 of the AQSE Exchange Rules and is therefore conditional on, inter alia, shareholder approval.
Following the Disposal, the Company will have disposed of all of its operating subsidiaries and will be deemed an Enterprise Company under the AQSE Exchange Rules. The Board’s intention is to exercise the Option to acquire the entire issued share capital of M3 Helium as set out in the announcement made by the Company on 27 June 2024. The exercise of the Option will constitute a reverse takeover under rule 3.6 of the AQSE Exchange Rules, therefore the Company will need to seek readmission of its ordinary to trading on the AQSE Growth Market.
There is no certainty that the Company’s option to acquire M3 Helium will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
Accordingly, Shareholder approval for the Disposal is being sought at the General Meeting to be held at 11.30 a.m. on 11 November 2024. The notice convening the General Meeting and setting out the Resolution to be considered at it is set out at the end of the circular. A summary of the action shareholders should take is set out in paragraph 8 of the circular .
Full details of the Disposal is set out in the extract from the circular set out below.
Copies of the circular and notice of General Meeting are available on the Company’s website: https://www.voyagerlife.uk
The Directors of the Company are responsible for the release of this announcement.
ENDS
Enquiries:
Mendell Helium plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti/Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
SI Capital Limited (Broker)
Nick Emerson |
Tel: +44 (0) 1483 413500 |
Stanford Capital Partners Ltd (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
Brand Communications (Public & Investor Relations)
Alan Green
|
Tel: +44 (0) 7976 431608 |
To all Shareholders,
Disposal of Plant Based Health & Wellness Business and Notice of General Meeting
1. Introduction
On 14 October 2024, Mendell Helium announced the conditional disposal of its plant based health & wellness business to Orsus, a private label turnkey solutions provider specialising in developing, formulating, marketing & sales of health and wellness products for global brands. The consideration comprises shares and warrants in Orsus as set out below.
The Disposal will constitute a fundamental change of business of the Company under Rule 3.7 of the AQSE Exchange Rules and is therefore conditional on, inter alia, the passing of the Resolution at the General Meeting.
Following the Disposal, the Company will have disposed of all of its operating subsidiaries and will be deemed an Enterprise Company under the AQSE Exchange Rules. The Board’s intention is to exercise the Option to acquire the entire issued share capital of M3 Helium as set out in the announcement made by the Company on 27 June 2024. Exercise of the Option will constitute a reverse takeover under rule 3.6 of the AQSE Exchange Rules, therefore the Company will need to seek readmission of its ordinary to trading on the AQSE Growth Market.
There is no certainty that the Company’s option to acquire M3 Helium will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
Accordingly, Shareholder approval for the Disposal is being sought at the General Meeting to be held at 11.30 a.m. on 11 November 2024. The notice convening the General Meeting and setting out the Resolution to be considered at it is set out at the end of this document. A summary of the action you should take is set out in paragraph 8 below.
Further details of the Disposal are set out below.
The purpose of this document is to give you details of the Disposal including the background to and reasons for it, to explain why the Directors consider it to be in the best interests of the Company and its Shareholders and stakeholders as a whole and recommend that you vote in favour of the Resolution to be proposed at the General Meeting.
2. Background to and reasons for the Disposal
As announced on 27 June 2024, the Company has an option to acquire M3 Helium Corp., a producer of helium which is based in Kansas and holds an interest in six wells. There is no certainty that the Company’s option to acquire M3 Helium will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
Pursuant to its proposed exercise of the Option, the Company is seeking to simplify its operations as it focuses on helium production. The Voyager business is currently loss-making and the effect of the Disposal will be that the Company can apply all of its cash resources on its new operations, subject to the exercise of the Option.
3. Information on Voyager
Voyager’s plant-based health and wellness operations comprise:
· Manufacturing facility in Perth, Scotland producing both products for own brand and third party customers (VoyagerCann)
· E-commerce and wholesale operations based in Perth, Scotland
· Three brands: Voyager, Ascend Skincare and Amphora
· Three retail stores in Scotland (St Andrews, Dundee and Edinburgh)
On 4 June 2024, Voyager announced that it had been successful in pitching for and winning a substantial new customer for VoyagerCann. The preliminary order for six product lines with an expected order value of over £30,000 has since been increased by plans to manufacture additional products for that customer, which is a leader in its field with retail stores across the UK and a strong online presence.
Since then, the Company has also received a series of orders worth over £38,000 for further products for one of its existing customers. That customer has since advised that certain of its products are expected to be stocked in well-known high street stores and, consequently, VoyagerCann’s order book is now stronger than at any time previously.
Within the Company’s own brand, Voyager, the most prominent customer is Pets at Home with four products available on Pets at Home’s website since November 2023. Furthermore, its Amazon profile has recently improved with a greater range of products now available for sale through its Prime channel.
In conjunction with Orsus, the Company is continuing to reinvigorate its e-commerce strategy with a plan for Voyager’s primary website to be re-written in Shopify and accompanied by a revised SEO (search engine optimisation), social media and digital marketing strategy. Shopify would provide more functionality and can also be integrated into the Company’s stores and used at external events (such as trade fairs).
With the low-cost acquisition of Amphora Health Limited earlier in the year, Voyager has 23 products validated on the FSA’s novel foods list, which the Board considers will be a key part of its e-commerce strategy. The acquisition also enabled entry into the potentially lucrative non-disposable vape market.
In the financial year ended 31 March 2024, the Company reported revenue of £304,000 with a gross margin of over 41%. Total assets were £929,000 and net assets £140,000. These figures are all substantially attributable to Voyager.
4. Principal terms of the Disposal
As announced on 14 October 2024, Mendell Helium entered into a share purchase agreement (“Share Purchase Agreement”) to dispose of Voyager’s plant based health and wellness business to Orsus. The Disposal is being effected by Orsus acquiring the Company’s wholly owned subsidiaries, being VoyagerCann Limited, Amphora Health Limited and Voyager Life Limited (the “Subsidiaries”), which, combined, own all of its health & wellness operations. The consideration for the Disposal is:
a. The issue of 9,000,000 new ordinary shares in Orsus (“Shares”) at a price of 5 pence per share to the Company, representing approximately 28% of the enlarged Orsus group
b. The issue of 6,000,000 new Orsus warrants (“Warrants”) to the Company, representing approximately 16% of the enlarged Orsus group’s existing share capital on a fully diluted basis
The Warrants will convert into new Orsus ordinary shares subject to the Voyager business contributing not less than £300,000 of revenues to the enlarged Orsus group and existing customers accounting for not less than £100,000 of such revenues in the first 12 months.
As the Disposal will result in a fundamental change in the Company’s business pursuant to Rule 3.7 of the AQSE Exchange Rules, it is therefore conditional on, inter alia, the passing of the Resolution at the General Meeting.
Pending shareholder approval, the Company and Orsus have agreed that 1 October 2024 is the effective date meaning that Orsus has assumed management control, and full profit & loss responsibility for Voyager from that date and Mendell Helium has no further obligation to contribute to the running costs of the Voyager plant based health & wellness business.
Prior to completion of the Disposal, Mendell Helium will transfer all of Voyager’s business into the Subsidiaries. This includes the operations of the Company’s retail shops in Dundee, St Andrews and Edinburgh. Agreements have been reached to sublet the shops in St Andrews and Edinburgh. Owing to rising rents since the Company commenced trading from these premises, Mendell Helium expects to make a small profit from the subletting (after taking account of legal fees and agents’ commissions in the first year). The Dundee shop will be the responsibility of Orsus.
It is Mendell Helium’s intention to transfer the Shares and Warrants to the Company’s shareholders on a pro rata basis. This will allow Mendell Helium to focus on its proposed new business of helium production in Kansas whilst also giving shareholders a direct and continuing stake in Voyager’s operations. Further details will be announced in due course.
The Share Purchase Agreement contains warranties given by the Company relating to the Company’s power and authority to enter into and perform its obligations under the transaction contemplated by the Share Purchase Agreement.
In addition, a number of business warranties are given by the Company to Orsus (for example in respect of employment, assets, trading, litigation and intellectual property). Orsus’ recourse against the Company for breach of warranties, indemnifications and otherwise under the Share Purchase Agreement is limited to certain agreed liability caps, with an overall maximum liability capped at £450,000 (being the value of the Shares).
The shares in the Subsidiaries will be transferred free of all encumbrances.
The Share Purchase Agreement is governed by the laws of England and Wales.
5. Information on Orsus
Orsus Therapeutics was established in 2021 as a special purpose acquisition vehicle to become an end-to-end provider of health and wellness solutions and products via a buy and build strategy. Through the acquisition of Voyager, it is seeking to become a leading private label turnkey solutions provider specialising in developing, formulating, marketing & sales of health and wellness products for global brands. Using Voyager’s facilities as its base in Perth, Scotland, Orsus has ambitious plans to build a leading health and wellness solutions business, offering a full creation and production vendor service to brands globally.
Aditya (“Harry”) Chathli, a founder Director of Orsus, is Non-Executive Chairman of Chill Brands Group PLC, a company which Nick Tulloch, CEO of Mendell Helium, is a Non-Executive Director.
Audited financial information on Orsus for the year ended 30 June 2023
Profit before taxation |
£(76,238) |
Total assets |
£339,646 |
Net assets |
£325,967 |
Cash |
£335,146 |
6. The effect of the Disposal on the Company
Following the Disposal, the Company will have disposed of all of its operating activities and will be an Enterprise Company under the AQSE Exchange Rules. The Board’s intention is to exercise the Option to acquire the entire issued share capital of M3 Helium as set out in the announcement made by the Company on 27 June 2024. There is no certainty that the Company’s option to acquire M3 Helium will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
The Disposal will result in the Company significantly reducing its working capital requirements.
7. General Meeting
A notice convening the General Meeting to be held at the Arran House, Arran Road, Perth, Perthshire PH1 3DZ at 11.30 a.m. on 11 November 2024 is set out at the end of this document. At the General Meeting, the Resolution will be proposed as an ordinary resolution, which means that to be passed, more than half the votes cast must be cast in favour of the resolution.
This Resolution is to approve the Disposal and to authorise the Directors to take all steps necessary or desirable to complete the Disposal. In order for the Resolution to be passed, a simple majority (being more than 50 per cent.) of votes cast (in person or by proxy) must be in favour of the Resolution.
8. Action to be taken
The Notice of General Meeting is set out on page 12 of this Circular and this letter explains the items to be transacted at the General Meeting.
A Form of Proxy for use at the General Meeting is enclosed. If you wish to validly appoint a proxy, the Form of Proxy should be completed and signed in accordance with the instructions printed thereon, and returned by post so as to be received by Share Registrars not later than 11.30 a.m. on 7 November 2024.
9. Recommendation
The Directors consider the Disposal to be in the best interests of the Company and the Shareholders as a whole and, accordingly, unanimously recommend that Shareholders vote in favour of the Resolution as they intend to do so in respect of their own beneficial holdings amounting, in aggregate, to 5,575,916 Ordinary Shares, representing approximately 12.7 per cent. of the Existing Share Capital.
Yours faithfully,
Eric Boyle
Chairman
2024 |
|
Publication and despatch of this document
|
25 October |
Latest time and date for receipt of Forms of Proxy
|
11.30 a.m. on 7 November |
General Meeting
|
11.30 a.m. on 11 November |
Result of General Meeting announced via RIS
|
11 November |
Notes:
(1) All of the above timings refer to London time unless otherwise stated.
(2) The dates and timing of the events in the above timetable and in the rest of this Document are indicative only and may be subject to change.
(3) If any of the above times or dates should change, the revised times and/or dates will be notified by an announcement through an RIS.
The following definitions shall apply throughout this document unless the context requires otherwise:
Definitions
The following definitions shall apply throughout this document unless the context requires otherwise:
“Act” |
the Companies Act 2006, as amended from time to time |
“AQSE” |
Aquis Stock Exchange Limited, a UK-based stock market providing primary and secondary markets for equity and debt products and which is permissioned as a Recognised Investment Exchange |
“AQSE Exchange Rules” |
the AQSE Growth Market Access Rulebook, which set out the admission requirements and continuing obligations of companies seeking admission to, and whose shares are admitted to trading on, the Access segment of the AQSE Growth Market |
“AQSE Growth Market” |
the Access Segment of the AQSE Exchange Growth Market operated by AQSE |
“Board” |
the board of Directors of the Company |
“CBD” |
cannabidiol, a phytocannabidiol found in the cannabis plant |
“Certificated” or “in certificated form” |
a share or other security which is not in uncertificated form (that is, not in CREST) |
“Circular” or “Document” |
this document dated 25 October 2024 |
“Company” or “Mendell Helium” |
Mendell Helium plc, a company incorporated in Scotland with registered number SC680788 |
“CREST” |
the relevant system (as defined in the CREST Regulations) for paperless settlement of share transfers and the holding of shares in uncertificated form which is administered by Euroclear UK & Ireland Limited |
“CREST Regulations” |
the Uncertificated Securities Regulations 2001 (SI 2001/3755) as amended |
“Directors” or “Board” |
Eric James Boyle, Nicholas (“Nick”) George Selby Tulloch and Jillian (“Jill”) Maree Overland as at the date of this document (but Jill Overland is stepping down from the Board on 6 November 2024) |
“Disposal” |
the proposed sale of the Company’s plant based health & wellness business to Orsus |
“Existing Share Capital” |
the 43,885,494 Ordinary Shares in issue at the date of this document, all of which are admitted to trading on the AQSE Growth Market; |
“FCA” |
the UK Financial Conduct Authority |
“Form of Proxy” |
the form of proxy accompanying this Document for use at the General Meeting |
“General Meeting” |
the general meeting of the Company to be held at 11.30 a.m. 11 November 2024 atArran House, Arran Road, Perth, Perthshire PH1 3DZ, notice of which is set out on page 12 of this Document |
“ISIN” |
the International Securities Identification Number |
“M3 Helium” |
M3 Helium Corp., a company incorporated and registered in the state of Delaware, U.S.A. with registration number 7514135 whose registered office is at 4601 E Douglas Ave, STE 150, Wichita, Kansas 67218, United States |
“Notice of General Meeting” |
the notice of General Meeting set out on page 12 of this Document |
“Option” |
the exclusive option agreement to acquire the entire issued and to be issued share capital of M3 Helium by issuing 57,611,552 new Ordinary Shares to M3 Helium’s shareholders |
“Ordinary Shares” |
ordinary shares of £0.01 each in the capital of the Company |
“Orsus” |
Orsus Therapeutics plc, a company incorporated and registered in England and Wales with registered number 13374907 |
“Recognised Investment Exchange” |
an investment exchange recognised by the FCA under the Financial Services and Markets Act 2000 |
“Registrar” |
Share Registrars Limited, the Company’s registrar |
“Regulatory Information Service” or “RIS” |
any channel recognised as a channel for the dissemination of information as defined in the glossary of terms in the AQSE Exchange Rules |
“Resolution” |
the resolution to be proposed at the General Meeting and as described on page 12 of this Document |
“SEDOL” |
the Stock Exchange Daily Official List Identification Number |
“Shareholders” |
the holders of Ordinary Shares from time to time |
“UK” or “United Kingdom” |
the United Kingdom of Great Britain and Northern Ireland |
“uncertificated” or “in uncertificated form” |
securities recorded on a register of securities maintained by Euroclear UK & Ireland Limited in accordance with the CREST Regulations as being in uncertificated form in CREST and title to which, by virtue of the CREST Regulations, may be transferred by means of CREST |
“Voyager” |
the operating subsidiaries of the Company, being VoyagerCann Limited, Amphora Health Limited and Voyager Life Limited which form the Company’s plant based health & wellness business |
Overview of M3 Helium and the Hugoton North Play
Mendell Helium, formerly Voyager Life plc, announced on 27 June 2024 that it has entered into an option agreement to acquire the entire issued share capital of M3 Helium through the issue of 57,611,552 new ordinary shares in Mendell Helium to M3 Helium’s shareholders. The exercise of the option will constitute a reverse takeover pursuant to AQSE Rule 3.6 of the Access Rule Book and is subject to, inter alia, publication of an admission document.
M3 Helium has interests in six wells in South-Western Kansas of which three (Peyton, Smith and Nilson) are in production. Five of the company’s wells are within the Hugoton gas field, one of the largest natural gas fields in North America. Significantly these wells are in the proximity of a gathering network and the Jayhawk gas processing plant meaning that producing wells can quickly be tied into the infrastructure.
The sixth well is in Fort Dodge and was tested in July 2024 as containing 5.1% helium composition. Although not within direct access to the gathering network, M3 Helium owns a mobile Pressure Swing Adsorptionproduction plant which could be used to purify the helium on site.
FORWARD LOOKING STATEMENTS
This announcement includes “forward-looking statements” which include all statements other than statements of historical facts, including, without limitation, those regarding the Company’s financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “similar” expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law.
Voyager Life #VOY – Final results for the period ended 31 March 2024, Proposed Change of Name and Notice of AGM
Voyager is pleased to provide the Company’s audited results for the period ended 31 March 2024.
As announced on 27 June 2024, the Company has an option to acquire M3 Helium Corp. (“M3 Helium”), a producer of helium based in Kansas and with an interest in six wells. There is no certainty that the Company’s option to acquire M3 Helium will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
Highlights in the Chairman’s statement include:
· Preparation of the admission document for the proposed acquisition of M3 Helium Corp. is underway
· Proposed change of name to Mendell Helium plc
· Heads of terms signed to dispose of the Company’s existing operations to another healthcare business
The Company’s annual report and accounts for the year ended 31 March 2024 and notice of annual general meeting (“AGM”) were posted on 27 September 2024 to Voyager’s shareholders. The AGM will be held at 10.00 am on Wednesday 6 November 2024, at the Company’s offices at Arran House, Arran Road, Perth, Perthshire PH1 3DZ.
Copies of the annual report and accounts and notice of AGM are available on the Company’s website: https://www.voyagerlife.uk
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
ENDS
Enquiries:
Voyager Life plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti/Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
SI Capital Limited (Broker)
Nick Emerson |
Tel: +44 (0) 1483 413500 |
Stanford Capital Partners Ltd (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
Brand Communications (Public & Investor Relations)
Alan Green
|
Tel: +44 (0) 7976 431608 |
Forward Looking Statements
These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not a guarantee of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
CHAIRMAN’S STATEMENT
It is a pleasure to present Voyager’s annual report and accounts for our financial year ended 31 March 2024.
My report this year begins post the year end as our most significant development took place after the financial year had concluded. On 27 June 2024, we announced that we had taken an option to acquire M3 Helium Corp. (“M3 Helium), a Kansas based producer of helium. Since taking that option, we have seen the ongoing development of that business and today M3 Helium has three wells in production and it expects a fourth to be in production before the end of October.
Investors may be aware of the growing global interest in helium, an element that has no natural substitute but a variety of everyday uses. Many people will think first of party balloons but medical, defence and space industries are the leading users of helium. There are many London listed natural resource companies – however, M3 Helium distinguishes itself as being a producer. And, by this, I mean that M3 Helium will be capable of finding, extracting, transporting and selling helium.
M3 Helium’s operations in Kansas comprise, in part, the Hugoton gas field, one of the oldest gas producing locations in the US – spanning parts of Kansas, Oklahoma and Texas. The Hugoton is also perhaps one of the best known producers of helium.
A significant competitive advantage for M3 Helium is its partnership with Scout Energy Partners (“Scout”), the largest operator in the Hugoton field in Kansas. M3 Helium’s wells are within reach of Scout’s gathering system and, more importantly, its Jayhawk gas processing plant, a facility which is estimated by Scout to produce around 5 per cent. of the world’s helium.
With M3 Helium’s location in such a prospective location and with its ready access to infrastructure, we believe we have an option to acquire a low-cost, fast growing business in one of the world’s most exciting natural resources regions.
Naturally it was a surprise to many when we announced our pivot away from plant-based health & wellness and into helium. It was not a decision that we took lightly.
We have said for some time now that the wider CBD and cannabis sectors were ready for consolidation. As is so often the case in newer, fast growing industries, a large number of companies were quickly established to chase the same goal. Forecasts predicted a rapid take up of cannabinoid-based products and investment understandably followed.
But as is also the case in newer sectors, forecasts in many ways were overly ambitious, the industry developed more slowly than predicted with slower take up amongst consumers than forecast and regulators understandably were cautious. Share prices came under pressure and investors became disillusioned.
At Voyager, we have always taken a cautious view. As far back as 2021 when we were just establishing the company, the board of directors predicted that the good times in the industry would not last forever. We implemented a low cost operating model and ensured we had a strong balance sheet. Our business developed well, as described more fully in the CEO’s statement, but our belief was that, to attract long term investment and to make use of our stock market listing, we needed to expand the business through acquisition.
Since the Company listed on AQSE, acquisition opportunities presented themselves. I wrote this time last year about our proposed acquisition of a Polish manufacturing and extraction facility, with a view to extend our business into Europe and complete our vertical integration. Ultimately our plans were defeated by the lengthy and unpredictable process of securing Polish regulatory approval.
More recently, and at the start of 2024, we launched a further ambitious initiative to acquire Northern Leaf plc, a cultivator of medical cannabis in Jersey, Channel Islands. The transaction would have created one of Europe’s few medical and over-the-counter cannabis operations, delivering scale and product diversity. The attractions were clear – Northern Leaf, which had spent around £30 million developing its facility was available to us for less than a tenth of that and investors were prepared to support the initiative. Disappointingly, the financial constraints of Northern Leaf could not outlast the fundraising process and this potential acquisition also failed.
As a board we explored other targets too. Although we were not successful, it is a testament to our team and our business model that, not only were we able to source a series of prospective merger partners but, in almost every case, the partner was a far larger business but available to us at a considerable discount to the investment they had made in the business themselves.
Ultimately, however, we could not wait indefinitely for the right opportunity and, as I indicated above, investor appetite for cannabis-based projects had waned. It is perhaps ironic that, as Voyager’s plant-based health & wellness business was winning new and bigger customers, we took the difficult decision to go down a different path.
Over the previous twelve months we had secured several substantial customers. Pets at Home is perhaps our best known retail outlet but I can also report that Voyager-made products are available to buy in some of the UK’s well known supermarkets, health stores and online retailers.
But building from this platform would require capital and the board, despite our successes and our proven ability to source acquisitions, could not be confident that investors would want to support us in these endeavours. Conversely, helium was a highly topical investment theme.
Some years ago, Nick Tulloch and I worked at Highlands Natural Resources plc (“Highlands”). Alongside us was Paul Mendell, former chairman of that company and the developer of some of its core projects. The three of us have stayed in touch and, before Voyager was founded, we looked at a different helium play in Kansas in the summer of 2020. The risk-reward profile of that opportunity was not favourable. The three of us went on to found Voyager, with Paul leaving ahead of the IPO to pursue other opportunities in the US – and ultimately to bring together a portfolio of assets under M3 Helium.
The combination of Voyager and M3 Helium, whilst unusual at first glance, in fact is reuniting business partners. It also marks the second occasion that the three of us have been involved in a pivot between natural resources and cannabis – Highlands performed its own transformation in 2019 and that company is now known as Chill Brands Group plc.
We stated in our shareholder circular on 1 July 2024, that we would put in place plans to dispose of our plant-based health and wellness operations as our focus is now on M3 Helium’s prospects in Kansas and I am pleased to report that we have signed non-binding heads of terms to dispose of the Company’s existing operations to another healthcare business. Completion will be subject to legally binding contracts and shareholder approval but, if our plans proceed as I expect them to, we will have successfully separated our helium and health & wellness operations whilst preserving our shareholders’ interests in the success of both. There is still work to be done but we hope to update shareholders shortly.
We also hope to conclude our acquisition of M3 Helium in Q4 2024. Under the Aquis Rules, the transaction is classified as a reverse takeover and, consequently, is subject to the publication of an admission document. Although our immediate focus on taking the option over M3 Helium was to accelerate the development of that business, I am pleased to report that preparation of the admission document is well underway.
Ahead of that, the time has come to give Voyager a new name and I am pleased to announce our proposed change of name to Mendell Helium plc, in recognition of the outstanding work that Paul Mendell has done in putting that business together.
As always, the Voyager board welcomes shareholder interaction and feedback and we hope to see as many of our investors as possible at our AGM on 6 November 2024. Notice for the meeting is set out at the end of this annual report.
Eric Boyle
Non-Executive Chairman
27 September 2024
CEO’S REVIEW
As our Chairman has written above, we have undertaken a change to our business following the end of the financial year. Although, by its nature, much of this annual report is backward looking on our operations during the year, our company is now very different to how we began the year.
When we report next year, we will report on our operations as a helium producer in Kansas and, based on what has been achieved in the short time since taking the option to acquire M3 Helium, I am confident that we have an exciting period ahead of us.
In the meantime, I am pleased to provide this summary of our achievements in the year to 31 March 2024. Just as we reported last year, the Company has four sources of income:
1. White label and private label skincare manufacturing through our VoyagerCann division
2. Sales through third party stores
3. Sales through our own stores in St Andrews, Edinburgh and Dundee
4. Online sales – comprising our own website along with third party sites and online marketplaces
I predicted last year that it would be items 1 and 2 in the above list, that would represent the biggest growth areas and that has indeed been the case. In November 2023, after an extensive courtship, we announced that Voyager’s pet products would be sold online by Pets at Home. This relationship has continued to develop with Pets at Home re-ordering regularly and Voyager making up the largest contributor of hemp products on its website.
£,000
Shop revenue 142
Trade sales 125
Website and other sales 37
As a rule, we do not disclose names of customers that we contract manufacture for but we have reported some of our successes. Since September 2023, we have been manufacturing products for arguably one of the UK’s highest profile CBD brands. As with Pets at Home, this partnership has continued to develop with further products made by us added to their range. Even at the time of writing, their biggest order to date is being processed in our manufacturing facility.
We were also pleased to announce in June 2024 that we had been selected to manufacture a new range for a very well known UK retailer, a leader in its particular field. Their indicative order was, at the time, our biggest to date although has since been surpassed by our CBD brand partner.
VoyagerCann
Following on from the above news, it is no surprise that VoyagerCann, established in February 2022, has become our best known division.
We offer two broad categories of service:
· White label which we define as manufacturing and supplying our existing formulations
· Private label which is either the adjustment of an existing formulation, perhaps for scent or CBD strength, or new product development
VoyagerCann offers a “shelf ready” solution providing, at the option of customers, a fully packaged, labelled and batch coded product supplied with all necessary accreditations for immediate sale. Many of our customers take advantage of this and it is not unusual for us to deliver orders directly to retailers, rather than to our customers themselves. Equally, we can provide supply products in bulk to our customers or a hybrid arrangement where we bottle products but customers carry out the final labelling and packaging themselves.
As our Chairman wrote above, the CBD industry is still characterised by a large number of brands, many of which are competing for the same end customer. Conversely, the number of specialist manufacturers of CBD products is considerably less and the board of directors felt that our company’s fastest route to success was to become the manufacturer of choice for the industry.
Our values of integrity, quality and transparency coupled with fair pricing placed us well within the industry.
Own stores
In the latter part of the pandemic, we opened three retail stores aiming to provide accurate and honest information on our products and CBD generally. Initially supported by grants and reduced business rates, this strategy, which was aimed at being part of the community to make CBD mainstream, had some initial success – even now it is the largest single revenue contributor to Voyager. However, rising costs, particularly employment and utilities, alongside flatter revenues have made this a difficult area in which to operate.
In line with our culture, we ran a tight operation but, even before we secured the option to acquire M3 Helium, it was apparent to the board that our resources could be more efficiently applied to our manufacturing, wholesale and e-commerce divisions.
As an extension of that, and alongside our proposed acquisition of M3 Helium, we have examined alternative solutions for our three shops and have been working with our landlords in respect of a possible sublet or assignment. This will reduce the operating costs for the business going forward and, as our Chairman has explained, following disposal we expect to give our shareholders the opportunity to remain invested in the business that we have built. We are fortunate that our shops are located in popular retail locations and we have already received interest from new prospective tenants.
Online
Since Voyager commenced operations, we have used WordPress to operate our websites but, during the course of this year, our team has been working on a plan to develop a new e-commerce website on the Shopify platform which we expect will give greater flexibility and capability. Coupled with this plan are a series of strategic initiatives to upgrade and extend our digital marketing reach. We have been working with IT consultants to deliver this and I am pleased that our new partners, following the combination of our two businesses, will continue this work.
It is well understood that online sales are capable of being higher margin than our other business lines and therefore replacing the investment in our bricks and mortar operations with an enhanced e-commerce strategy represents a natural development of our business at this stage.
Acquisition of Amphora Health Limited
On 30 January 2024, we announced that we had entered into an agreement to acquire Amphora Health Ltd (“Amphora”), owner of the Amphora and Infused Amphora brands which comprise a range of CBD oils, vapour products and accessories. The acquisition duly completed in March 2024.
The consideration payable was the issue of 416,666 new ordinary shares in Voyager. In addition, a further 416,666 new ordinary shares may be issued in the event that sales of Amphora or Infused Amphora branded products exceed £100,000 over the 24 month period from completion.
Infused Amphora is a British CBD wellness brand founded in 2020. The entire collection of its premium products are all natural, THC free and designed to help with a variety of everyday conditions. Most importantly, and a primary reason for our acquisition, is that the brand has 23 ingestible CBD products validated on the FSA’s novel foods list, a potentially highly valuable asset in the CBD industry.
Also importantly, given potential changes in UK legislation, Amphora vapour products are not disposable but are currently sold in cartridges for use with a rechargeable battery and the formula can also be sold as an e-liquid for customers to refill their preferred vapour products themselves.
Amphora had inventories of £17,000 at the time of our acquisition and also owns several online domains, as well as registered trademarks in the UK, European Union, Republic of Korea and China. The Amphora website will be combined with Voyager’s new website but the products on the novel foods list, coupled with the trademarks, provides considerable scope to monetise that brand.
The operations of Amphora were moved to Voyager’s existing premises and therefore the acquisition did not entail any increase in overheads. No members of the Amphora team were employed by Voyager and none of the premises or storage facilities occupied by Amphora were included in the acquisition. On this basis, we have treated the transaction as an asset acquisition rather than a business acquisition.
Operations
Voyager employs 24 people of which 10 are based in our head office in Perth and the remainder work in our stores. As in previous years, we were the beneficiary of government employment grants but, as alluded to above, these were less than before at £2,400.
Aside from wage inflation and utility charges, costs were for the most part steady. Certain ingredient pricing increased as a result of conflicts around the world, particularly the Ukraine, but we were generally able to offset this through bulk purchases or more competitive sourcing of other products. VoyagerCann is also able in most instances to pass higher raw material costs onto our customers.
Outlook
As our Chairman has said, we have signed heads of terms to dispose of our health & wellness operations to another healthcare business. We are now working on concluding contracts and thereafter we will publish a circular convening a general meeting for shareholder approval of the transaction. As long term investors will know, we have worked hard to develop Voyager as a well recognised CBD and plant-based health & wellness business and therefore, as we move to become a helium producing business, it was important to us to find a means of disposing of these operations in a manner than enabled existing shareholders to retain the benefit of any future upside. We expect to announce further details shortly.
We have had a busy summer since announcing our option to acquire M3 Helium. That company now has three producing wells and, as Rost comes online shortly, that will soon become four. Together with M3 Helium, we have developed good relations with counterparties and other participants in the Kansas helium industry and we expect that to place our new business in good stead as we continue that expansion.
This coming year is about the operations of M3 Helium in Kansas and I look forward to reporting as Mendell Helium plc in the future.
Nick Tulloch
Chief Executive Officer
27 September 2024
Link here for the full financial statements
Voyager Life #VOY – Result of GM, Director-PDMR Shareholding, Issue of Equity & Warrants
Voyager is pleased to announce that at the General Meeting held earlier today, all resolutions were duly passed.
Issue of Equity
Following shareholder approval at the General Meeting the Company has issued 22,239,150 new ordinary shares (being the Second Tranche Shares). The Company has also issued 14,407,803 Investor Warrants and 900,000 Broker Warrants, in aggregate 15,307,803 Warrants have been issued in connection with the Fundraise.
Director Participation & Director / PDMR Shareholding
As part of the Fundraise, Eric Boyle, Non-Executive Chairman, and Fetlar Capital Limited (a company controlled by Nick Tulloch, Chief Executive Officer and his spouse) have subscribed, in aggregate, for £50,000 of Fundraise Shares (“Director Participation”) as set out in the table below.
Director |
Amount subscribed for in the Fundraise |
Number of Fundraise Shares |
Number of Investor Warrants |
Resultant shareholding following Second Admission |
Nick Tulloch |
£25,000* |
833,333 |
416,666 |
2,988,442 |
Eric Boyle |
£25,000 |
833,333 |
416,666 |
2,587,474 |
*Participation made through Fetlar Capital Limited (a company controlled by Nick Tulloch, Chief Executive Officer and his spouse)
Related Party Transaction
The Director Participation (the “Transaction”) is a related party transaction for the purposes of Rule 4.6 of the AQSE Growth Market Access Rulebook. Jill Overland, the director of Voyager independent of the Transaction confirms that, having exercised reasonable care, skill and diligence, the Transaction is fair and reasonable insofar as the shareholders of Voyager are concerned.
Admission
Application has been made for the Second Tranche Shares to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market. Second Admission is expected to occur at 8:00 am on or around 19 July 2024.
Total voting rights
Following Second Admission, the Company’s enlarged share capital will comprise 43,218,494 ordinary shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 43,218,494. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the circular published by the Company on 1 July 2024.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
ENDS
Enquiries:
Voyager Life plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti/Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
SI Capital Limited (Broker)
Nick Emerson/Nick Briers |
Tel: +44 (0) 1483 413500 |
Stanford Capital Partners LLP (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
Brand Communications (Public & Investor Relations)
Alan Green |
Tel: +44 (0) 7976 431608 |
FORWARD LOOKING STATEMENTS
This announcement includes “forward-looking statements” which include all statements other than statements of historical facts, including, without limitation, those regarding the Company’s financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “similar” expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law.
Voyager Life #VOY – Posting of Circular and Notice of General Meeting
Voyager announces, that further to the announcement of 27 June 2024, the Circular together with a Notice of General Meeting to be held at Arran House, Arran Road, Perth, Perthshire PH1 3DZ at 11.00 a.m. on 18 July 2024, has been posted to Shareholders and is available to view on the Company’s website at https://voyagerlife.uk/our-investors/.
Expected timetable of principal events
2024 |
|
Publication and despatch of the Circular
|
1 July |
First Admission and dealings in the First Tranche Shares expected to commence on AQSE |
8.00 a.m. on 4 July |
Latest time and date for receipt of Forms of Proxy
|
11.00 a.m. on 16 July |
General Meeting
|
11.00 a.m. on 18 July |
Result of General Meeting announced via RIS
|
18 July |
Second Admission and dealings in the Second Tranche Shares expected to commence on AQSE
|
8.00 a.m. on 19 July |
Crest accounts (where relevant) expected to be credited
|
19 July |
Share certificates (where relevant) expected to be despatched no later than
|
26 July |
Notes:
(1) All of the above timings refer to London time unless otherwise stated.
(2) The dates and timing of the events in the above timetable and in the Document are indicative only and may be subject to change.
(3) If any of the above times or dates should change, the revised times and/or dates will be notified by an announcement through an RIS.
Admission and Fundraising statistics
Issue Price per New Ordinary Share |
3 pence |
Number of Ordinary Shares in issue prior to the Fundraise |
14,402,888 |
Number of Fundraise Shares |
28,815,606 |
Number of First Tranche Shares to be issued |
6,576,456 |
Number of Ordinary Shares in issue following First Admission and issue of the First Tranche Shares |
20,979,344 |
Number of Second Tranche Shares to be issued(1) |
22,239,150 |
Number of Ordinary Shares in issue following Second Admission and issue of the Second Tranche Shares(1) |
43,218,494 |
Percentage of the Further Enlarged Share Capital represented by the Fundraise Shares |
66.7 per cent. |
Number of Investor Warrants to be issued following Second Admission |
14,407,803 |
Number of Broker Warrants to be issued following Second Admission |
900,000 |
Gross proceeds of the Fundraise(1) |
£864,468 |
AQSE Symbol |
VOY |
SEDOL |
BLD3FF2 |
ISIN |
GB00BLD3FF28 |
LEI
|
2138100XIUQ3AHRZ6UF89 |
1Assuming authority is granted at the General Meeting to issue the Second Tranche Shares and Warrants
1. Introduction
On 27 June 2024, Voyager announced that it had entered into an option agreement to acquire the entire issued share capital of M3 Helium Corp., a producer of helium based in Kansas, USA. The Option gives Voyager the right to acquire M3 Helium through the issue of 57,611,552 New Ordinary Shares to M3 Helium’s shareholders, representing 57 per cent. of the issued share capital of Voyager as enlarged by the New Ordinary Shares following the Option and the Fundraise.
The exercise of the Option will constitute a reverse takeover pursuant to AQSE Rule 3.6 of the Access Rule Book and is subject to, inter alia, publication of the Admission Document in due course.
Highlights of the Acquisition
· M3 Helium is already producing helium and natural gas from its first well and has economic interests in four other wells believed to be economic to operate
· Through an arrangement with a local partner, M3 Helium has access to existing infrastructure to transport and process helium in large quantities (specifically a pipeline to a processing plant)
· The Directors believe that M3 Helium has the ability, subject to funding and availability of new leases, to scale up its projects to new drilling sites based on expected resource capacity from an independent resource report
· M3 Helium owns an existing modular hybrid plant to process and enrich helium – utilised in Fort Dodge where there is no immediate access to infrastructure
The Company has conditionally raised £864,468 through the Fundraise of 28,815,606 New Ordinary Shares at an issue price of 3 pence per New Ordinary Share. For every two New Ordinary Shares issued pursuant to the Fundraise, investors will receive one Investor Warrant allowing the holder to subscribe for an additional new Ordinary Share in the Company at an exercise price of 6 pence per Ordinary Share, exercisable within two years up until the second anniversary of the date of Second Admission.
In connection with the Fundraise, the Company will issue, on completion of the Fundraise, 900,000 Broker Warrants. The Broker Warrants shall be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the second year anniversary of Second Admission. The Broker Warrants will not be tradeable, nor transferable or CREST-enabled. If the Resolutions are not passed, the Company will not be able to issue the Broker Warrants until such time as it has authority to do so.
The proceeds of the Fundraise will be utilised to:
· fund the development of M3 Helium’s operations;
· M3 Helium expects to drill the first of several further wells at Hugoton North Play;
· costs for the preparation of an Admission Document in connection with the proposed re-admission to trading on AQSE Growth Market; and
· general working capital purposes for the Company.
The Fundraise will be undertaken in two tranches. The first tranche of 6,576,456 New Ordinary Shares (“First Tranche Shares”) will utilise existing share authorities and will be issued pursuant to the Fundraise with admission of the First Tranche Shares to trading on Aquis Stock Exchange AQSE Growth Market expected to occur on or around 4 July 2024 (“First Admission”). The second tranche of 22,239,150 New Ordinary Shares (“Second Tranche Shares”), including the Warrants, will be issued and admitted to trading on Aquis Stock Exchange AQSE Growth Market (“Second Admission”) subject to approval by Voyager’s shareholders at the General Meeting.
Following completion of the Acquisition, the Directors expect to realise some cost synergies in areas such as finance, administration and marketing, but the primary benefit of the Acquisition is anticipated by the Directors to be through the development of M3 Helium’s assets in Kansas and, specifically, increasing production and therefore revenue.
The consideration for the Acquisition is approximately £1.7 million, at the Issue Price, comprising 57,611,552 new Ordinary Shares. Coupled with the Fundraise, the Directors consider that the overall terms of this transaction compare favourably to the valuation of other helium assets, both on UK stock exchanges and elsewhere.
The Directors intend to dispose of Voyager’s existing plant-based health and wellness operations following the reverse takeover.
There is no certainty that the Option will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
The purpose of the Document is to set out the background to, and the reasons for, the Acquisition and the Fundraise and to provide details of the proposed Resolutions in relation to the Fundraise. The Document explains why the Directors consider the Acquisition and Fundraise to be in the best interests of the Company and its Shareholders as a whole. It also recommends that all Shareholders vote in favour of the Resolutions to be proposed in the General Meeting, as the Directors intend to do so themselves in respect of their own beneficial holdings of Ordinary Shares.
2. Overview of the Acquisition
M3 Helium owns economic interests in five wells in Kansas as well as a helium production plant. M3 Helium is already producing helium and generating revenue from one of these wells with two of the other wells to be shortly tied into nearby infrastructure. A fourth well has been tested successfully as economic with testing of a fifth underway. With proven geology, the Directors believe that M3 Helium has the ability, subject to funding and availability of new leases, to rapidly scale up its projects to new drilling sites based on expected resource capacity from an independent resource report.
|
|
M3 Helium operates in Kansas, USA from two locations:
Hugoton Field: North Play
The Hugoton gas field, located primarily in southwestern Kansas, western Oklahoma, and the Texas panhandle, is one of the largest natural gas fields in North America, deriving its name from the town of Hugoton, Kansas. Discovered in 1927, this field which covers around 31,080 square kilometres has significantly contributed to the natural gas supply in the United States. Over its long history, more than 12,000 wells have been drilled in the Hugoton field.
The field’s cumulative production is substantial, with over 30 trillion cubic feet of natural gas produced since being discovered. Additionally, it has yielded substantial quantities of natural gas liquids and helium.
M3 Helium’s North Play potentially extends to 250 sections with recoverable gas, with each section being approximately 640 acres (one square mile). Production to date has indicated a helium content of 1.25 per cent., a concentration that compares very favourably to other parts of the Hugoton gas field. Analogous wells drilled by other operators within the North Play have averaged over 0.44 bcfg per well, meaning that, with four wells per section, M3 Helium estimates a potential of up to 440+ bcfg of recoverable gas across the entire area. At a constant 1.25 per cent. helium content, M3 Helium estimates potential recoverable helium of over 5.5 bcf across the entire area.
The north region of the field has been historically largely undeveloped because of the combination of high nitrogen content, which makes natural gas economically challenging, coupled with infrastructure costs. These economic impediments changed on 1 April 2024 when Scout Energy acquired the only existing pipeline thereby providing M3 Helium with a direct path to commercial sale, utilising Scout Energy’s Jayhawk helium plant in Kansas. It is this access to nearby infrastructure that makes the North Play particularly significant. Helium sale prices to date at the Jayhawk helium plant have been US$550 per MCF, less a 20 per cent. processing fee and M3 Helium is currently discussing revised arrangements on quantum and pricing going forward. However, reflecting some recent price weakness in the global helium market, M3 Helium is assuming lower pricing going forward as modelled in its well analysis described below.
An independent resource report prepared by WSP for the benefit of M3 Helium on 25 January 2024 provided the following probabilistic contingent resource estimates*:
Unit |
P90 Low Estimate |
P50 Best Estimate |
P10 High Estimate |
|
Natural Gas |
Bcf |
787.7 |
1,068.9 |
1,442.2 |
Helium |
MMcf |
16,513.6 |
23,038.4 |
31,994.7 |
*The resource report has not been prepared to the standards of a competent person’s report in line with the requirements for UK listed companies and, furthermore, it is addressed solely to M3 Helium. Other parties are unable to rely on the resource report.
Vertical wells in the North Play are forecast by M3 Helium to cost approximately US$300,000 to complete with a 29-month projected payback based on the following assumptions:
Gas production |
95 mcf/day |
Helium content |
1.25% |
Annual decline |
8% |
Helium sale price |
$450/mcf* |
Natural gas price |
$3.47/mcf |
Royalties |
19% |
Processing fees |
20% |
*M3 Helium models a flat helium price in determining financial returns from its wells although most market commentators predict a rising price over the 30 year well life.
M3 Helium estimates that the average life of vertical wells in the Hugoton North Play is circa 30 years. Whilst, to date, it has solely drilled vertical wells, management’s longer-term strategy is to drill horizontal wells at this location. Upfront costs would be higher at circa US$2 million for a horizontal well of 10,000 feet (approximately 2 miles) in length with staged fracks every 220 feet. M3 Helium predicts an increased production rate from horizontal wells because of the greater wellbore length exposed to the pay zone and the Company expects to explore this option later in the year.
Fort Dodge
Fort Dodge Prospect is in Ford County, Kansas. M3 Helium owns the lease and existing well in the area (Rost 1-26). Helium concentrations at Fort Dodge have been higher to date at 4.6 per cent. but, unlike the North Play, there is no access to infrastructure meaning that M3 Helium will utilise its modular hybrid plant to process and enrich produced helium. Purified helium is expected to be collected on site by its customer with terms being negotiated.
The Fort Dodge lease allows for two additional similar wells to be drilled in addition to Rost 1-26.
Vertical wells in Fort Dodge are more expensive, being estimated by M3 Helium at US$800,000 due to depth and there is also the need for on-site processing and an injection well (for the disposal of saltwater). However, Fort Dodge wells have a 6 month projected payback based on the following assumptions:
Gas production |
300 mcf/day |
Helium content |
4.6% |
Annual decline |
10% |
Helium sale price |
$450/mcf |
Natural gas price |
$3.47/mcf |
Royalties |
20% |
Restructuring of M3 Helium
Prior to entering into the Option, M3 Helium underwent a restructuring whereby title to certain of its assets was transferred into the company in return for issuing shares to the asset owners. The purpose of the restructuring was to ensure that all assets were held by a single legal entity and so that Voyager was able to enter into the Option with M3 Helium. The Option will expire if it has not been exercised by Voyager by 30 September 2024.
The Acquisition will be classified as a reverse takeover under Rule 3.6 of the AQSE Growth Market Access Rule Book and, consequently, exercising the Option will be subject to the publication of the Admission Document and re-admission to trading on the AQSE Growth Market.
Financial information on M3 Helium
M3 Helium was incorporated on 16 June 2023 and prepared its first unaudited accounts to the period ended 31 December 2023. In that period, it recorded total operating expenses of US$24,724 and did not generate any income. Cash outflows in that period, including both its investment activities and operating expenses, comprised US$1.14 million before financing activities of US$1.6 million. The total assets, including cash resources of US$454,385, comprised US$1.57 million. There were no liabilities at the period end.
M3 Helium has also provided Voyager with up to date unaudited financial information prepared on an interim basis to 31 May 2024. This reflects the ongoing development of its Kansas wells and total assets at that date are shown as US$3.59 million with US$320,250 of outstanding liabilities. Cash outflows in the period 1 January – 31 May 2024, reflecting these development activities, comprised US$2.19 million before financing activities of US$1.7 million.
M3 Helium presents its accounts in US GAAP but, following completion of the Acquisition and once it is a subsidiary of the Company, it will report in IFRS. There are certain differences in the two standards for companies in the natural resources industry including:
· Expense recognition: Under IFRS, expense recognition is generally principles-based. Expenses are recognised when it is probable that a decrease in future economic benefits related to a decrease in an asset or an increase in a liability has occurred and can be measured reliably. Under US GAAP, expense recognition is more rules-based and follows a matching principle, meaning expenses should be matched with the revenues they help to generate.
· Leases: Under IFRS all leases are recognised on the balance sheet (with some exceptions for short-term and low-value leases), with a right-of-use asset and corresponding lease liability. US GAAP applies more distinctions between finance leases and operating leases, affecting the pattern of expense recognition in the income statement.
· Exploration and evaluation (E&E) costs: Companies have the flexibility to either expense or capitalise E&E costs. If capitalised, they are classified as intangible or tangible assets and assessed for impairment when facts and circumstances suggest that the carrying amount may exceed recoverable amount. Under US GAAP, E&E costs are generally expensed as incurred but allows capitalisation of costs associated with successful exploration efforts, while unsuccessful efforts are expensed.
· Capitalisation Criteria: IFRS also provides a broader criteria for the capitalisation of development costs; specifically costs can be capitalised if it is probable that they will generate future economic benefits and the costs can be measured reliably.
· Impairment Reversal: Impairment testing is required when there are indicators of impairment. Assets are impaired if their carrying amount exceeds the recoverable amount. IFRS allows for the reversal of impairment losses (excluding goodwill) if conditions change whereas US GAAP does not. Under US GAAP, it is necessary to assess if the carrying amount is recoverable based on undiscounted cash flows. If not recoverable, the impairment loss is measured as the excess of carrying amount over fair value.
· Joint Arrangements: Under IFRS, joint arrangements are classified as either joint operations or joint ventures. Joint operations involve rights to assets and obligations for liabilities, with proportional consolidation. Joint ventures involve rights to net assets and are accounted for using the equity method. US GAAP also accounts for joint ventures using the equity method but proportional consolidation is generally not permitted.
The Directors expect there to be adjustments to M3 Helium’s historic financial track record when it is consolidated with Voyager but they do not consider these changes to be significant to investors’ understanding of the Acquisition or the prospects of the Company overall.
3. Helium
Helium Production
Helium is a non-toxic, colourless, odourless, tasteless, inert, monoatomic gas. It is the first noble gas in the periodic table of elements and its boiling point is the lowest among all of the elements. These properties make helium absolutely unique – there is no substitute, and no natural or manufactured replacement for it.
Whilst there is a large amount of helium in the atmosphere, it is prohibitively expensive to extract it from this source because its concentration is so low and, to do so, requires specialist equipment. It is estimated that distilling helium from the atmosphere would cost over US$1,500 per Mcf of helium so all commercial helium supply generally comes from underground reservoirs in which helium produced by the radioactive decay of uranium and thorium is concentrated and trapped over hundreds of millions of years.
Helium has historically been produced as a by-product of certain conventional natural gas projects (less than 3 per cent. of natural gas deposits have more than trace amounts of helium) and those sources account for the bulk of the world’s helium supply today. The process of drilling for helium is identical to drilling for natural gas, allowing for the use of the same rigs, tools and personnel in these operations. However, exploration for helium is challenging and requires significant technical knowledge related to helium generation (from the underground decay of uranium and thorium), concentration and migration through formation fluids, exsolution and migration to traps in a gas phase and reservoir evolution through time. Specialised expertise and methods across multiple disciplines are required to effectively search for new helium fields.
Once a commercially viable helium reserve has been discovered and development wells have been drilled, there are two stages in the production of helium which can be combined into a single plant for larger deposits of helium.
|
|
Helium Separation and Purification
Because even 0.35 per cent. helium in a bulk-gas is considered a high-concentration, the first step is to separate the helium from the other components of the bulk gas stream. This can be accomplished through three principal technologies, which are often combined depending on the composition of the gas stream:
Membrane Separation
The helium content of a gas can be upgraded or purified by using high-pressure membranes which either concentrate or purify helium through selective diffusion of relatively smaller gas molecules through microscopic pores in the medium. This technology is relatively new for helium separation applications and may not be suitable for longer-lifetime projects.
PSA or TSA
Pressure-Swing Adsorption (PSA) or Temperature-Swing Adsorption (TSA). These technologies use temperature or pressure to cause selective adsorption of different sized gas molecules into a medium with a large surface area consisting of uniformly sized pore spaces. These technologies are time-tested, reliable, and can be deployed at small scale. The downside is that this process is less efficient than cryogenic separation, in terms of both energy use and product losses during the process.
Cryogenic Separation
Similar to the air separation units (ASUs) that are deployed worldwide in the industrial gas business, this technology uses low temperatures to cause different gases to condense off as a liquid in a fractionation tower. This process is ideally suited to helium, which has the lowest condensation point of any gas, but requires large scale for efficiency and has a higher initial capital cost.
Helium Liquefication
In order to economically ship helium around the globe, like LNG, purified helium gas is liquefied prior to shipping so that it will fill a smaller volume. Liquid helium product also addresses a wider market, including those end-users who require the low temperatures of liquid helium. In the larger global helium plants, the gas is liquefied and stored in specialised 40-foot long ISO intermodal shipping containers. Due to the high-value of helium, it can also be economically shipped regionally as a gas in high-pressure tube trailers, although shipping costs for helium gas are higher than for liquid helium.
Uses of Helium
Helium’s unique properties make it essential for vital technologies that affect our lives every day.
Advanced Medical Imaging Equipment
Helium is used in advanced medical imaging equipment like MRIs, providing the super cooling needed for the creation of powerful magnetic fields by these devices.
Advanced Scientific Research
Helium is used in a variety of advanced scientific research applications where super cooling and powerful magnetic fields are required. Applications such as mag-lev trains, superconducting electrical transmission lines and quantum computing are all examples.
Space Exploration & Defence Applications
Helium is used in space exploration and defence applications. Helium has unique properties such that it is the only gas that can be used to pressurise the liquid fuels that power the rockets driving space exploration, as well as the blimps and airships that have other applications within the atmosphere.
Manufacturing
Helium is required for the manufacture of semiconductors, fibre optics, liquid crystal displays and many other applications. By way of an everyday example, helium was required to make the equipment and components necessary to make computers and Internet connection systems work.
Global uses of helium
|
Source: Transparency Market Research, 2023
Demand for Helium
New potential sources of demand for helium are appearing all the time. From new, low-cost reusable rockets for space launches, to the advancement of nuclear fusion research, to testing autonomous floating internet infrastructure, to new therapies targeting cancer cells with ion beams, helium’s unique properties make it increasingly vital to our present and our future.
Global Helium Market
Helium is a vital element for a number of major technologies that affect our lives every day, but the ability of existing and planned sources of helium supply to meet future demand is highly uncertain.
A number of factors have come together to create a precarious situation, starting with the 1996 decision by the US government to sell off nearly its entire stockpile of helium, stored in a depleted natural gas field in Amarillo, Texas. This created an increase in supply and prices of helium have arguably been artificially depressed prices for much of the last decade. Until a few years ago, this facility was the only place in the world to store helium, so all of the helium that has been sold out of this reserve has already been consumed.
In addition to the depletion of the US government helium reserve, falling oil and gas prices caused by the advent of shale drilling, have caused the cancellation or significant delay of a number of major energy projects. Helium has historically been produced as a by-product in a few large conventional oil & gas projects, which happened to have a high helium content. Many projects of this type with helium potential have been cancelled in the last few years, as they have been replaced by spending on oil & gas production from shale, which cannot trap or produce significant quantities of helium. There are no major projects under development in North America that can replace the loss of helium supply from US government stockpile sales. Recent shortages have made existing helium demand less elastic and quickly-maturing new sources of helium demand could increase the rate of demand growth. From new low-cost reusable rockets for space launches, to the advancement of nuclear fusion, to autonomous floating Internet infrastructure, to new therapies targeting cancer cells with ion beams, helium’s unique physical properties make it increasingly vital to our present and our future.
US helium market
|
Five major fields/facilities (BLM storage, LaBarge, Hugoton, Algeria and Qatar) supply around 80 per cent. of global upstream helium. A similar number of large players control the distribution, which is often executed on privately negotiated contracts. Data on current supply/demand/prices are therefore not widely disclosed and create uncertainty around precise estimates. Furthermore, existing helium supply is structurally fragile, as an outage of one (of the limited number of) suppliers could have disproportionate effects.
|
Source: GrandView Research
The Company expects a continued increase in demand underpinned by the lack of substitutes for helium in its main markets of MRIs and high-end science/engineering, including rapid growth in state-funded/private space exploration, pressure/purge applications and rising demand for semiconductors. A shortage in the early part of the last decade forced price spikes incentivising new supply (based on LNG plant start-ups), driving prices back to more normal levels. We believe current supply constraints should continue to support pricing and may support marked increases.
4. The Fundraising, Director Participation and Issue of Warrants
The Company has conditionally raised gross proceeds of £864,468 through a fundraise of 28,815,606 New Ordinary Shares at an issue price of 3 pence per New Ordinary Share. For every two New Ordinary Shares issued pursuant to the Fundraise, investors will receive one warrant allowing the holder to subscribe for an additional Ordinary Share in the Company at an exercise price of 6 pence per Ordinary Share, exercisable within two years.
The First Tranche Shares will utilise existing share authorities with First Admission expected to occur on or around 4 July 2024. The Second Tranche Shares, including the Warrants, will be issued and Second Tranche Admission will occur subject to approval by Voyager’s shareholders at the General Meeting.
Eric Boyle, Non-executive Chairman, and Fetlar Capital Limited (a company controlled by Nick Tulloch, Chief Executive Officer and his spouse), each intend to invest £25,000 in the Fundraise and will therefore each receive New Ordinary Shares and Investor Warrants as part of the Second Tranche Shares.
The Fundraise, which is not being underwritten, is conditional, inter alia, upon admission to trading on AQSE. The New Ordinary Shares will rank pari passu in all respects with the Ordinary Shares including the right to receive all dividends and other distributions declared, paid or made after the date of issue.
Previously, New Ordinary Shares issued by the Company have been eligible for Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) purposes providing tax benefits to certain investor groups. With its change in business activities, Voyager will apply to HMRC for clarification whether these tax efficient qualifications will remain in place following the Acquisition.
In connection with the Fundraise, the Company will issue, on completion of the Fundraise, 900,000 Broker Warrants. The Broker Warrants shall be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the second year anniversary of Second Admission. The Broker Warrants will not be tradeable, nor transferable or CREST-enabled. If the Resolutions are not passed, the Company will not be able to issue the Broker Warrants until such time as it has authority to do so.
Shareholders should note that First Admission is not conditional upon Second Admission occurring and in the event that the Resolutions are not passed, Second Admission may not occur and the Company would not receive the funds from the Second Tranche Shares, which would limit the amount of working capital available to it. In addition, the Warrants will not be issued in the event that the Resolutions are not passed and therefore persons subscribing First Tranche Shares on First Admission would not, in such circumstances, receive any Investor Warrants.
5. Use of Proceeds and Strategy
The Fundraise will raise proceeds of £864,468 for the Company which will be applied towards:
· the development of M3 Helium’s operations;
· M3 Helium expects to drill the first of several further wells at Hugoton North Play;
· preparation of the Admission Document; and
· general working capital purposes.
The Company expects to exercise the Option on re-admission to trading on AQSE Growth Market of the enlarged group and, immediately following the Fundraise, will commence preparation of the Admission Document. The Company intends to make a loan facility of up to US$500,000 (the “Loan Facility”) available to M3 Helium to advance its drilling programme with its Kansas assets.
The Loan Facility has been prepared on the basis of an arm’s length commercial agreement between Voyager and M3 Helium for a term of up to one year. The Loan Facility and bears an interest rate of 6 per cent. per annum starting from the date on which the funds are received and ending upon the term date. The Loan Facility contains restrictions on M3 Helium taking on external finance and is structured to ensure it ranks in priority to M3 Helium’s other obligations. Drawdowns under the Loan Facility must be for a specified purpose, namely the ongoing development of M3 Helium’s business.
6. Existing health and wellness operations
Following the Acquisition, the Directors will put plans in place to dispose of Voyager’s existing plant-based health and wellness operations. These comprise:
(i) Manufacturing facility in Perth, Scotland producing both products for Voyager and third party customers
(ii) E-commerce and wholesale operations based in Perth, Scotland
(iii) Three retail stores in Scotland (St Andrews, Dundee and Edinburgh)
Although the Directors have concluded that the scale of these operations is not likely to be large enough in the short term to justify being a public company, there have been considerable successes in recent months. On 4 June 2024, Voyager announced that it had been successful in pitching for and winning a substantial new customer for its manufacturing division, VoyagerCann. Arrangements with this customer are still being finalised but outline terms are for a preliminary order for six product lines with an initial order value of up to £30,000 and thereafter further orders to meet demand. This customer is a leader in its field with retail stores across the UK, a strong online presence and supplies to equally well-known third-party stores and has already started discussions with Voyager on “phase 2” of its product roll out which will comprise further additions to the range.
The Company announced at the time that these arrangements represent potentially its biggest customer win since Voyager was established. However, later that day, the Company also received an indicative order worth £38,000 for a new range of products for one of its existing customers. VoyagerCann’s order book is now stronger than at any time previously.
Voyager sells over 70 of its own product lines in store, online and through third party outlets and carries over 400 SKUs in its three retail stores. VoyagerCann continues to grow its reputation and, in addition to manufacturing Voyager, Ascend Skincare and Amphora branded products, also supplies customers who in turn supply some of the UK’s best known supermarkets, health stores and TV shopping channels. Within Voyager’s own brand, and not taking into account the new customer described above, the Company’s most prominent customer is Pets at Home with four products available on Pets at Home’s website since November 2023.
Following its success with its petcare range, Voyager contracted in the Spring of 2024 with Unified Retail to manage sales of its pet range and other products on Amazon. In the months since the Company began working with Unified Retail, its Amazon profile has already improved with a greater range of products now available for sale through its Prime channel.
The Company has also been exploring a reinvigoration of its e-commerce strategy and has developed a plan with a specialist IT consultant for Voyager’s primary website to be re-written in Shopify and accompanied by a revised SEO, social media and digital marketing strategy. Shopify would provide more functionality and can also be integrated into the Company’s stores and used at external events (such as trade fairs). The IT consultant is experienced in marketing CBD products online, including using sponsored advertisements, and the Board forecasts that sales, both B2C and B2B, are likely to benefit immediately from these plans. Initial set up is likely to cost in the range of £10,000 with monthly support costs variable in line with sales. Once set up, Voyager’s overall IT expenditure is expected to fall as Shopify could address three separate solutions currently being used.
With the low-cost acquisition of Amphora Health Limited earlier in the year, Voyager now has 23 products validated on the FSA’s novel foods list, which the Board considers will be a key part of its e-commerce strategy. Just as significantly, the acquisition enables Voyager to enter the potentially lucrative non-disposable vape market and the VoyagerCann team have completed preparations to commence manufacturing the Amphora formulations. The Board believes that VoyagerCann will be able to produce a vape range that is significantly differentiated from the competition but at a very competitive price.
As previously announced, in line with others on the high street, Voyager’s retail stores had a difficult second half to the 2023 calendar year but the Company reduced staffing and revised its product mix to address this challenge. In recent months, the beginnings of a sales recovery across the stores have been observed.
With these successes, and even taking account of the low valuations currently ascribed to CBD and cannabis companies at present, the Board believes that a disposal of these operations will be possible in the near term and, importantly, will not be a cash drain on the Enlarged Group in the meantime. The Company’s manufacturing, e-commerce and wholesale operations can be profitable without the burden of the expenses of being a public company and, despite challenges on the high street, market rents for at least two of Voyager’s shops are now materially higher than the rent paid by the Company so transferring these leases in the short term is a realistic possibility.
7. Appointment of new director
Following completion of the Acquisition, it is proposed that Paul Mendell, co-founder of M3 Helium will join the board of directors of Voyager.
Paul is an oil and gas producer and co-founder of two UK listed companies – Iofina plc, an AIM listed iodine producer, and Highlands Natural Resources, later known as Zoetic International where he was chairman of that company, now known as Chill Brands Group. Paul has owned interests in over two-hundred producing oil and gas wells in the US which he has developed or from properties he acquired and were subsequently acquired by larger firms including Anadarko, EnCana, Noble, Oxy and others. He is a geologist and a well-respected developer of new concepts in exploration for oil, gas, iodine and other commodities. Paul also founded Mendell Energy; a Denver based independent oil and gas producer, sold for US$12 million in 2012.
A further announcement will be made in due course.
8. Admission
Application has been made for First Tranche Shares to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market. First Admission is expected to occur at 8:00 am on or around 4 July 2024. Application will also be made for the Second Tranche to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market with Second Admission expected to occur as soon as practicable following the approval of shareholders at the forthcoming General Meeting. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Total voting rights
Following First Admission, the Company’s Enlarged Share Capital will comprise 20,979,344 ordinary shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 20,979,344. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Investor Warrants will be issued over 14,407,803 new Ordinary Shares pursuant to the Fundraise. In addition, Broker Warrants will be issued over 900,000 new Ordinary Shares. In aggregate, 15,307,803 Warrants will be issued in connection with the Fundraise and 20,101,891 warrants will be in issue following Second Admission.
Previously Ordinary Shares have been eligible for Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) purposes providing tax benefits to certain investor groups. With its change in business activities, Voyager will apply to HMRC for clarification whether these tax efficient qualifications will remain in place following the Acquisition.
9. General Meeting
The Directors do not currently have authority to issue the Second Tranche Shares, the Investor Warrants and the Broker Warrants and, accordingly, the Board is seeking the approval of Shareholders to issue the Second Tranche Shares, the Investor Warrants and the Broker Warrants at the General Meeting. In addition, the Directors propose to seek additional authority to allot further Ordinary Shares in the future to provide flexibility and to allow the Company some ability to take advantage of opportunities which may present themselves in the future.
A notice convening the General Meeting to be held at the Arran House, Arran Road, Perth, Perthshire PH1 3DZ at 11.00 a.m. on 18 July 2024 is set out at the end of the Document. At the General Meeting, the following Resolutions will be proposed:
Resolution 1 is proposed as ordinary resolutions, which means that to be passed, more than half the votes cast must be cast in favour of each resolution. Resolution 2 is proposed as a special resolution, which means that to be passed, at least three-quarters of the votes cast must be cast in favour of the resolution.
Resolution 1 – Authority to allot shares
This resolution seeks shareholder approval to grant the Directors the authority to allot shares in the Company, or to grant rights to subscribe for or convert any securities into shares in the Company (“Rights”), pursuant to section 551 of the Act (the “Section 551 authority”). The authority contained in the resolution will be limited to an aggregate nominal amount of £1,000,000. If approved, the Section 551 authority shall, unless renewed, revoked or varied by the Company, expire nine months from the date of the passing of this resolution or, if earlier, at the conclusion of the next annual general meeting of the Company. The exception to this is that the Directors may allot shares or grant Rights after the authority has expired in connection with an offer or agreement made or entered into before the authority expired. This power is in addition to, and not in substitution for, all existing powers granted at the 2023 Annual General Meeting of the Company.
Resolution 2 – Disapplication of pre-emption rights
This resolution seeks shareholder approval to grant the Directors the power to allot equity securities (as defined by section 560 of the Act) or sell treasury shares of the Company pursuant to sections 570 and 573 of the Act (the “Section 570 and 573 power”) without first offering them to existing shareholders in proportion to their existing shareholdings. The power is limited to allotments for cash in connection with pre-emptive offers, subject to any arrangements that the Directors consider appropriate to deal with fractions and overseas requirements, and otherwise pursuant to non-pre-emptive offers for cash up to a maximum nominal value of £1,000,000. If approved, the Section 570 and 573 power shall expire nine months from the date of the passing of this resolution or, if earlier, at the conclusion of the next annual general meeting of the Company. The exception to this is that the Directors may allot equity securities after the power has expired in connection with an offer or agreement made or entered into before the power expired.
In both cases, the power proposed to be granted by the Resolutions is in addition to, and not in substitution for, all existing powers granted at the 2023 Annual General Meeting of the Company.
10. Action to be taken
The Notice of General Meeting is set out in the Circular and this letter explains the items to be transacted at the General Meeting.
A Form of Proxy for use at the General Meeting is enclosed. If you wish to validly appoint a proxy, the Form of Proxy should be completed and signed in accordance with the instructions printed thereon, and returned by post so as to be received by Share Registrars not later than 11.00 a.m. on 16 July 2024.
11. Recommendation
The Directors consider the Fundraising and the conferring of additional shareholder authority to be in the best interests of the Company and the Shareholders as a whole and, accordingly, unanimously recommend that Shareholders vote in favour of the Resolutions as they intend to do in respect of their own beneficial holdings amounting, in aggregate, to 3,909,250 Ordinary Shares, representing approximately 27.1 per cent. of the Existing Share Capital.
Shareholders should note that First Admission is not conditional upon Second Admission occurring and in the event that the Resolutions are not passed, Second Admission may not occur and the Company would not receive the funds from the Second Tranche Shares, which would limit the amount of working capital available to it. In addition, the Warrants will not be issued in the event that the Resolutions are not passed and therefore persons subscribing for First Tranche Shares on First Admission would not, in such circumstances, receive any Investor Warrants.
The Directors unanimously recommend that Shareholders vote in favour of the Resolutions to be proposed at the General Meeting.
Yours faithfully,
Eric Boyle
Chairman
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
ENDS
Enquiries:
Voyager Life plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti/Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
SI Capital Limited (Broker)
Nick Emerson/Nick Briers |
Tel: +44 (0) 1483 413500 |
Stanford Capital Partners LLP (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
FORWARD LOOKING STATEMENTS
This announcement includes “forward-looking statements” which include all statements other than statements of historical facts, including, without limitation, those regarding the Company’s financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “similar” expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law.